Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on the day's biggest business stories
Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Illustration: Sarah Grillo/Axios
Startups are competing to use biosynthesis to produce the cannabinoids found in different strains of cannabis.
Why it matters: The market for various types of CBD — a non-psychoactive component in cannabis — for medical and nutraceutical purposes is growing rapidly, and biosynthesis promises a cheaper and more controllable method of production than growing plants.
By the numbers: According to a recent research note from Raymond James, the present size of the global cannabinoid biosynthesis market opportunity is around $40 billion.
- A number of startups are moving into the biosynthesized cannabinoid space, which Raymond James analyst Rahul Sarugaser has written is "synthetic biology's next killer app."
Background: The conventional method of obtaining cannabinoids like CBD involves cultivating cannabis plants that contain the strain wanted, and then extracting the desired chemicals.
- Because some of the most in-demand cannabinoids occur in very low concentrations in nature, a lot of plant matter is needed, which means production costs can be higher than $50,000/kg.
- Growing cannabis can be "backbreaking work," notes Dennis O'Neill, the chief investment officer of the biosynthesis startup Biomedican, and regulatory issues mean that whole cannabis crops need to be destroyed if levels of THC — the psychoactive ingredient in marijuana — are too high.
How it works: In biosynthesis, microbes like yeast and bacteria are engineered to produce large quantities of a single cannabinoid in a fermentation process that works similarly to beer brewing.
- As a result, biosynthesis companies will be able to produce expensive cannabinoids at a much lower price and without fears of contamination.
- "We can harvest every day, as opposed to a plant that requires 55 days to grow," says O'Neill.
Flashback: A number of the companies involved in biosynthesis got their start years ago trying to use a similar process to produce advanced biofuels.
- Those efforts never really bore fruit, in large part because it was far too difficult to compete on price with cheap oil.
- That looks to be less of a problem with expensive cannabinoids.
What to watch: Whether biosynthesis companies are able to successfully move from demo-scale efforts, like the one announced last week by Berkeley-based Demetrix, to full-scale production.